Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report | Zendy

Hongkai Zhuang | Zendy; Zuyi Ma | Zendy; Yanxia Wu | Zendy; Zi Yin | Zendy; Zhixiang Jian | Zendy; Chuanzhao Zhang | Zendy; Baohua Hou | Zendy

Open Access

Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report

Author(s) -

Hongkai Zhuang,

Zuyi Ma,

Yanxia Wu,

Zi Yin,

Zhixiang Jian,

Chuanzhao Zhang,

Baohua Hou

Publication year - 2020

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2020.02.45

Subject(s) - medicine , vincristine , rituximab , epirubicin , cyclophosphamide , chemotherapy , adjuvant , adjuvant chemotherapy , prednisone , adjuvant therapy , surgery , oncology , lymphoma , cancer , breast cancer

Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neoadjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHOP) chemotherapy alleviated the symptom of plasma cell type of Castleman disease (PCCD) as well as downsized the tumor to provide an opportunity for radical surgical resection. It would contribute to the treatment for borderline resectable or unresectable UCD in the future.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research